Ástralía - enska - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - ethinylestradiol, quantity: 20 microgram; levonorgestrel, quantity: 100 microgram - tablet, sugar coated - excipient ingredients: calcium carbonate; maize starch; povidone; glycol montanate; lactose monohydrate; macrogol 6000; magnesium stearate; sucrose; purified talc - microlevlen ed is indicated for the prevention of pregnancy.

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - levonorgestrel, quantity: 30 microgram - tablet, sugar coated - excipient ingredients: lactose monohydrate; maize starch; povidone; purified talc; magnesium stearate; sucrose; macrogol 6000; calcium carbonate; glycol montanate - oral contraception

Bandaríkin - enska - NLM (National Library of Medicine)

physicians total care, inc. - norethindrone acetate (unii: 9s44lic7oj) (norethindrone - unii:t18f433x4s), ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u) - norethindrone acetate 1 mg - microgestin ® 1/20, microgestin ® fe 1/20 , microgestin ® 1.5/30, and microgestin ® fe 1.5/30 are indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception. oral contraceptives are highly effective. table i lists the typical accidental pregnancy rates for users of combination oral contraceptives and other methods of contraception. the efficacy of these contraceptive methods, except sterilization, depends upon the reliability with which they are used. correct and consistent use of methods can result in lower failure rates. oral contraceptives should not be used in women who currently have the following conditions: - thrombophlebitis or thromboembolic disorders thrombophlebitis or thromboembolic disorders - a past history of deep vein thrombophlebitis or thromboembolic disorders a past history of deep vein thrombophlebitis or thromboembolic disorders - cerebral vascular or coronary artery disease cerebral vascular or coronary artery dise

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

media preparation unit, dept microbiology and immunology, the university of melbourne - ct922 - microbiological culture media ivds - culture media for the selection, growth, isolation and/or differentiation of microorganisms including bacteria, yeast and fungi.

Singapúr - enska - HSA (Health Sciences Authority)

mundipharma pharmaceuticals pte. ltd. - fluticasone propionate; formoterol fumarate dihydrate - aerosol, metered - 50 mcg/actuation - fluticasone propionate 50 mcg/actuation; formoterol fumarate dihydrate 5 mcg/actuation

Singapúr - enska - HSA (Health Sciences Authority)

mundipharma pharmaceuticals pte. ltd. - fluticasone propionate; formoterol fumarate dihydrate - aerosol, metered - 125 mcg/actuation - fluticasone propionate 125 mcg/actuation; formoterol fumarate dihydrate 5 mcg/actuation

Singapúr - enska - HSA (Health Sciences Authority)

mundipharma pharmaceuticals pte. ltd. - fluticasone propionate; formoterol fumarate dihydrate - aerosol, metered - 250 mcg/actuation - fluticasone propionate 250 mcg/actuation; formoterol fumarate dihydrate 10 mcg/actuation

Bandaríkin - enska - NLM (National Library of Medicine)

mayne pharma inc. - norethindrone acetate (unii: 9s44lic7oj) (norethindrone - unii:t18f433x4s), ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u) - norethindrone acetate 1 mg - microgestin and microgestin fe are indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception. oral contraceptives are highly effective. table i lists the typical accidental pregnancy rates for users of combination oral contraceptives and other methods of contraception. the efficacy of these contraceptive methods, except sterilization, depends upon the reliability with which they are used. correct and consistent use of methods can result in lower failure rates. table i: lowest expected and typical failure rates during the first year of continuous use of a method % of women experiencing an unintended pregnancy in the first year of continuous use lowest method expected* typical** (no contraception) ...................... (85) (85) oral contraceptives .................... 3 combined ................................ 0.1 n/a*** progestin only ........................ 0.5 n/a*** diaphragm with spermicidal cream or jelly .......................... 6 20 spe

Bandaríkin - enska - NLM (National Library of Medicine)

rpk pharmaceuticals, inc. - norethindrone acetate (unii: 9s44lic7oj) (norethindrone - unii:t18f433x4s), ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u) - microgestin and microgestin fe are indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception. oral contraceptives are highly effective. table i lists the typical accidental pregnancy rates for users of combination oral contraceptives and other methods of contraception. the efficacy of these contraceptive methods, except sterilization, depends upon the reliability with which they are used. correct and consistent use of methods can result in lower failure rates. table i: lowest expected and typical failure rates during the first year of continuous use of a method % of women experiencing an unintended pregnancy in the first year of continuous use lowest method expected* typical** (no contraception) ...................... (85) (85) oral contraceptives .................... 3 combined ................................ 0.1 n/a*** progestin only ........................ 0.5 n/a*** diaphragm with spermicidal cream or jelly .......................... 6 20 spe

Bandaríkin - enska - NLM (National Library of Medicine)

mayne pharma inc. - norethindrone acetate (unii: 9s44lic7oj) (norethindrone - unii:t18f433x4s), ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u) - microgestin 24 fe is indicated for use by women to prevent pregnancy [see clinical studies (14)] . the efficacy of microgestin 24 fe in women with a body mass index (bmi) of > 35 kg/m2 has not been evaluated. do not prescribe microgestin 24 fe to women who are known to have the following conditions: - a high risk of arterial or venous thrombotic diseases. examples include women who are known to: smoke, if over age 35[ see boxed warning and warnings and precautions (5.1)] have deep vein thrombosis or pulmonary embolism, now or in the past[see warnings and precautions (5.1)] have inherited or acquired hypercoagulopathies[see warnings and precautions (5.1)] have cerebrovascular disease[see warnings and precautions (5.1)] have coronary artery disease[see warnings and precautions (5.1)] have thrombogenic valvular or thrombogenic rhythm diseases of the heart (for example, subacute bacterial endocarditis with valvular disease, or atrial fibrillation)[see warnings and precautions (5.1)] have uncontrolle